GENERVON BIOPHARMACEUTICALS TO PRESENT ITS NEURODEGENERATION PLATFORM AT WUXI HEALTHCARE CEO ROUNDTABLE 2019
March 3, 2019
SHANGHAI, CHINA
Genervon will present its neurodegeneration therapeutic treatments platform at the 2019 WuXi Healthcare Forum CEO Roundtable on March 5 at the St. Regis Hotel, Shanghai, showcasing the cutting edge of Genervon’s R&D and clinical stage drug pipelines.
Genervon Biopharmaceuticals, a US clinical-stage biopharmaceutical company, discovered an endogenous embryonic stage regulator of the human nervous system and developed a multi-target drug for fatal neurological disorders.
This cationic peptide regulator, GM6, passes through the blood-brain barrier, demonstrates excellent safety and efficacy in clinical trials, and modulates key biomarkers in patients.
Genervon holds more than 80 patents worldwide and is currently planning Phase 2B/3 clinical trials for ALS and Phase 2 clinical trials for Parkinson’s Disease, Alzheimer’s Disease, and Multiple Sclerosis indications.
While actively developing GM6 in the US, Genervon is interested in out-licensing or co-developing GM6 to Chinese pharmaceutical companies/investors for the China market.
Click here for Presentation Summary >
健能万生化制药企业(Genervon Biopharmaceuticals) 在三月五日在中国上海靜安瑞吉酒店2019 药明康德健康产业论坛CEO圆桌环节，展示健能万的创新产品，技术，成果和风釆。
健能万生化制药企业 (Genervon Biopharmaceuticals) 是一家美国临床阶段的生化制药企业。健能万发现了一种人类神经系统内源性的胚胎发育阶段调节因子，并将其转化为一款可以治疗致命的神经系统疾病的多靶点药物－GM6。
GM6是一种正电性的短肽调节因子，可以成功通过血脑屏障，显示出多种积极的临床结果，并且可以调节患者体内的关键生物标志物水平。健能万在全球拥有80多项专利, 目前正在计划开展GM6对于肌萎缩侧索硬化症 (ALS)治疗的2B和3期临床试验,以及帕金森病(PD), 阿尔茨海默氏病(AD)和多发性硬化症(MS)的2期临床试验。
健能万在美国积极开发GM6的同时, 有兴趣和中国制药公司或投资者达成战略合作,共同开发和独家授权许可协议，以便在中国更快的进行临床试验以及获得商业批准。